Intelligently
mining the market

Investors + news

We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe.

see our business strategy in action

Eagle Pharmaceuticals 2021 Annual Report

Investors Menu

Investors

Featured Press Release

-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline
See More
-- Featured speakers and KOLs include: Scott Tarriff, Herm Cukier, Dr. Richard Dutton, Dr. Prem Fort, Dr. TJ Gan, Dr. Andre Kalil, Dr. Joseph Pergolizzi and Dr. Eugene Vortsman -- -- Topics include the clinical and scientific rationale for the Company’s hospital-based products and pipeline
See More
-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of 2023 -- -- CAL02 is being developed as an adjunct to the clinically indicated
See More

Upcoming Events & Presentations

No items found.

Change % Volume Data as of 10/15/2022 11:59 PM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

In-Site
Communications, Inc.
Lisa M. Wilson,
212-452-2793

For all other media inquiries, please contact us.